Health science is big business. And Battelle, the Columbus research institution, is involved in health science in a big way, according to the Columbus Dispatch.
In the final installment of a four-part series on Battelle, Dispatch writer Kevin Mayhood takes a look at some of Battelle’s contracts to research and develop health and medical technologies and devices – currently $1 billion-worth.
BioLabs Pegasus Park Cultivates Life Science Ecosystem
Gabby Everett, the site director for BioLabs Pegasus Park, offered a tour of the space and shared some examples of why early-stage life science companies should choose North Texas.
Battelle is expanding its health science practice. This month, the institution announced it would invest more than $200 million to update and expand biotechnology laboratories, and build a health and life sciences research lab at two Columbus-area campuses, Mayhood said.
Battelle is expecting biotech businesses to grow rapidly in the next five years, so it wants to be ready. Now is a strategic time to invest, despite the economy’s woes.
“There are no more wonder drugs,” Barbara Kuntz, president of Battelle’s health and life sciences section, told the Dispatch. But as pharmaceutical, medical device and biologics companies move toward personalized medicine, “There will be many more drugs that need development and testing,” Kuntz said.
The 35 Battelle employees in Cleveland develop programs and services in technology-based economic development, technology commercialization and strategic technology positioning in industries that include life sciences and advanced manufacturing.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Read the whole Battelle series here.
Here are more stories that deserve a read:
- Cleveland Clinic’s Dr. Steve Nissen warns consumers to protect themselves (Plain Dealer)
- Cleveland Clinic IT chair to join in national dialogue about health care reform (Plain Dealer)
- Why Medicare pays so much for cancer drugs (WSJ Health blog)
- Bristol-Myers’s reliance on three drugs casts doubt on strategy (NYT)
- Leaders of health care workers union are relieved of duty (LA Times)
- Cardiovascular drug developer Cogentus goes belly up (VentureBeat)
- At one academic medical center: “Profitability” trumps doing “The Right Thing” (Health Care Renewal blog)
